⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL206083 | 0.83 | — | — | |
| SCHEMBL207087 | 0.82 | — | — | |
| SCHEMBL16835468 | 0.80 | HTR2A (0.32) | — | |
| SCHEMBL23612086 | 0.79 | — | — | |
| SCHEMBL2481710 | 0.77 | — | — | |
| SCHEMBL2388464 | 0.77 | HTR2A (0.31) | — | |
| SCHEMBL942937 | 0.75 | HTR2A (0.32) | — | |
| SCHEMBL20888200 | 0.73 | — | — | |
| SCHEMBL21591143 | 0.73 | — | — | |
| SCHEMBL1555745 | 0.73 | HTR2A (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 443 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11939300-B2 | Compounds and methods for treating autoimmune disorders by targeting HLA-DQ2 | IMMUNOMOLECULAR THERAPEUTICS, INC. (US) | 2024-03-26 | — | — | US | claimed |
| WO-2023051793-A1 | COMPOUND AS INHIBITOR OF COMPLEMENT FACTOR D, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF | 武汉朗来科技发展有限公司 | 2023-04-06 | — | — | WO | claimed |
| EP-3972590-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | Merck Sharp & Dohme Corp. (US) | 2022-03-30 | — | — | EP | claimed |
| US-20210275499-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Metrion Biosciences Limited (GB) | 2021-09-09 | — | — | US | claimed |
| EP-3817742-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Metrion Biosciences Limited (GB) | 2021-05-12 | — | — | EP | claimed |
| EP-3414247-B1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN LA ROCHE (CH) | 2021-04-21 | — | — | EP | claimed |
| WO-2020236688-A1 | NATRIURETIC PEPTIDE RECEPTOR A AGONISTS USEFUL FOR THE TREATMENT OF CARDIOMETABOLIC DISEASES, KIDNEY DISEASE AND DIABETES | MERCK SHARP & DOHME CORP. (US) | 2020-11-26 | — | — | WO | claimed |
| US-10618897-B2 | Spiroindolinones as DDR1 inhibitors | HOFFMANN-LA ROCHE INC. (US) | 2020-04-14 | — | — | US | claimed |
| WO-2020008206-A1 | HETEROCYCLIC SULFONAMIDE DERIVATIVES AND PHARMACEUTICAL USES THEREOF | Metrion Biosciences Limited (GB) | 2020-01-09 | — | — | WO | claimed |
| US-20190071444-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2019-03-07 | — | — | US | claimed |
| EP-3414247-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | H. Hoffnabb-La Roche Ag (CH) | 2018-12-19 | — | — | EP | claimed |
| WO-2017137334-A1 | SPIROINDOLINONES AS DDR1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2017-08-17 | — | — | WO | claimed |
| US-20240228464-A9 | TETRAZOLE CONTAINING APOPTOSIS SIGNAL-REGULATING KINASE 1 INHIBITORS AND METHODS OF USE THEREOF | ENANTA PHARM INC (US) | 2024-07-11 | — | — | US | disclosed |
| US-20240217955-A1 | SUBSTITUTED 4-AMINOISOINDOLINE-1,3-DIONE COMPOUNDS, COMPOSITIONS THEREOF, AND METHODS OF TREATMENT THEREWITH | SIGNAL PHARMACEUTICALS, LLC | 2024-07-04 | — | — | US | disclosed |
| WO-2024137764-A1 | NOVEL COVALENT INHIBITORS AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. (US) | 2024-06-27 | — | — | WO | disclosed |
| US-20240207224-A1 | MACROCYCLIC CHALCONE-AMIDE DERIVED ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2024-06-27 | — | — | US | disclosed |
| WO-2009099736-A2 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-13 | — | — | WO | disclosed |
| US-20090197863-A1 | BENZOXAZOLE CARBOXAMIDE INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-08-06 | — | — | US | disclosed |
| WO-2009029375-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | WO | disclosed |
| US-20090062268-A1 | NOVEL INHIBITORS OF POLY(ADP-RIBOSE)POLYMERASE (PARP) | LEAD THERAPEUTICS, INC. (US) | 2009-03-05 | — | — | US | disclosed |